

August 30, 2019

Announcements

YCC Appoints Five New Leaders

I am pleased to announce several leadership appointments for Yale Cancer Center, including two new leadership positions to help bolster Yale Cancer Center's research mission in the coming years.

Please join me in welcoming the following faculty to their new appointments:

- Megan King, PhD, Co-Research Program Leader for Radiobiology & Radiotherapy
- Carla Rothlin, PhD, Co-Research Program Leader for Cancer Immunology
- Katerina Politi, PhD, Co-Research Program Leader for Signal Transduction
- Don Nguyen, PhD, Assistant Cancer Center Director for Research Development
- Mark Lemmon, PhD, FRS, Associate Cancer Center Director for Basic Science

from the desk of

Charles S. Fuchs, MD, MPH
Director, Yale Cancer Center
and Physician-in-Chief
Smilow Cancer Hospital

Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center

Megan King, PhD,
Associate Professor
of Cell Biology, joins
Joseph Contessa,
MD, PhD, as Co-
Leader of
the **Radiobiology &
Radiotherapy
Research Program.**

Megan's research is generating unique insights into chromatin organization and dynamics, with a particular focus on DNA repair and the biology of BRCA cancer susceptibility genes. Together with Joe, Megan will lead the next wave of scientific discovery with our Radiobiology & Radiotherapy program members.



Carla Rothlin, PhD,
Dorys
McConnell Duberg
Professor
of Immunobiology
and Pharmacology
and Howard Hughes
Medical Institute
Scholar, joins Lieping
Chen, MD, PhD, and
Mario Sznol, MD, as
Co-Leaders of the
**Cancer
Immunology
Research Program.**

Carla's elucidation of the TAM (Tyro3, Axl, Mer) signaling pathway has launched an exciting new avenue of research in immunology, which also avails exciting new therapeutic strategies for inhibition or enhancement of the inflammatory response. The joint leadership between Carla, Mario, and Lieping is a dynamic team and will undoubtedly accelerate discovery, innovation, and high-impact translation in Cancer Immunology and Immuno-Oncology at our Center.



**New Breast Cancer Screening
Guidelines Prompting Questions**

[Read More >>](#)



**If your Olive Oil Tastes Like This, it
Could Help Fight Cancer Cells**

[Read More >>](#)



**Why Even Breast Cancer Survivors
Should Get Tested for BRCA**

[Read More >>](#)

Katerina Politi, PhD, Associate Professor of Pathology, joins David Stern, PhD, and Daniel Petryak, MD, to lead our **Signal Transduction Research Program.**

Katie's innovative research has characterized pivotal mechanisms that underlie sensitivity and resistance to targeted therapies and immune checkpoint inhibition and her ongoing work is defining novel approaches to overcome therapeutic resistance. Katie's accomplishments and commitment to innovation, combined with David and Dan's continued leadership, will ensure the enduring success of our Signal Transduction Program as they unveil the Program's next chapter.



Don Nguyen, PhD, Associate Professor of Pathology and of Medicine (Medical Oncology), and a member of Yale Cancer Center's Signal Transduction Research Program, has been appointed as the inaugural **Assistant Cancer Center Director for Research Development.**

Don's laboratory has developed unique approaches and model systems to understand the biology of cancer metastases, thereby unleashing the potential for novel cancer therapies. In his new role for the Cancer Center, Don will lead intramural funding programs, identify new funding opportunities to broaden the funding support of our membership, and craft strategies to promote new collaborations and areas of investigations within our Center. These are vitally important priorities for our Cancer Center,



Radiologic Tech Rides in Closer to Free for Herself and Her Patients

[Read More >>](#)




Yale Cancer Center Researcher Wins Prestigious Early Investigator Award

[Read More >>](#)



Join Smilow Cancer Hospital on Facebook



Latest Posts:

On August 27 in 1942, physicians at Yale made medical history as they administered the first use of intravenous chemotherapy as a cancer treatment in the United States.

and I am confident that Don's leadership will further propel scientific progress at Yale.

Finally, **Mark Lemmon, PhD, FRS**, Co-Director of the Cancer Biology Institute (CBI), has been appointed **Associate Cancer Center Director for Basic Science**, to oversee basic science priorities and maximize interaction between basic, translational, population, and clinical investigators across the YCC community. Mark's great success in leading the CBI, in conjunction with CBI co-Director Joseph (Yossi) Schlessinger, PhD, positions Mark as an ideal leader of our exceptional talented and accomplished basic research community in our Cancer Center. In assuming this new role, Mark will transition his leadership of the Signal Transduction Research Program to David Stern, PhD, Daniel Petrylak, MD, and Katerina Politi, PhD.



Oncology Nursing Symposium

Join your nursing colleagues for a symposium highlighting the latest advances in cancer care and treatment on Saturday, **September 21** at Lawrence + Memorial Hospital in New London. Hosted by the Smilow Cancer Hospital Care Center in Waterford, the program will feature presentations on a variety of topics.

[Learn More and Register >>](#)

Notables

Jason Cai, PhD, Assistant Professor of Radiology and Biomedical Imaging and a member of Yale Cancer Center's Radiobiology and Radiotherapy Research Program, has been awarded an Exploratory/Development **R21 grant** from the **National Institutes of Health (NIH)**. Dr. Cai's research project titled, "Development of BBB Permeable PD-L1 PET Imaging Agents," will involve synthesis and radiolabeling a library of small molecule



[Read More >>](#)



[Read More >>](#)

Dr. Nita Ahuja, Chief of Surgery at Yale New Haven Hospital, joined us for a discussion on surgical advances on Yale Cancer Answers on Connecticut Public Radio. Tune in to hear her insights and more on her research focus on pancreatic cancer.



[Read More >>](#)

Our radiation oncology team provides the most advanced technology to our patients, while putting quality and safety

PD-L1 ligands as potential PET imaging probes, aiming to find one probe that could penetrate the blood-brain barrier and allow for the quantification of PD-L1 in brain tumor or metastasis.

Leah Ferrucci, PhD, MPH, Assistant Professor of Epidemiology and a member of Yale Cancer Center's Cancer Prevention and Control Research Program, has been selected to participate in **SWOG's Young Investigator Training Course** in Seattle next month.

Carla Vanina Rothlin, PhD, has been named the **Dorys McConnell Duberg Professor of Immunobiology**. Dr. Rothlin is also a Professor of Pharmacology, Co-Leader of the Yale Cancer Center Cancer Immunology Research Program, and a Howard Hughes Faculty Scholar. She co-directs a laboratory with Sourav Ghosh, Associate Professor of Neurology and Pharmacology. Their lab has identified the function of the TAM receptor tyrosine kinases in the negative regulation of the magnitude of the immune response.

The **Genetics, Genomics and Epigenetics Research Program** is proud to welcome **James Clune, MD**, to its program. Dr. Clune is an Assistant Professor in the Department of Surgery and cares for patients in our Melanoma Program at Smilow Cancer Hospital. Dr. Clune has a background in translational research and a high-volume clinical practice focused on the treatment of melanoma patients. His goal at Yale Cancer Center is to harness his translational research and clinical care skillset to help translate the institution's strong research in the genetics of metastatic disease and prognostic and diagnostic markers into additional clinical trials in melanoma.

Research Highlights

first. Learn more about the benefits of treatment by a Smilow Cancer Hospital radiation oncologist.



[Read More >>](#)


Riley Norwood, a senior at Cheshire Academy, stopped by Smilow Cancer Hospital to deliver a check to the Breast Center. Riley crafted and sold over 250 pink ribbon key chains to help in the Smilow support breast cancer research. We are so grateful to Riley for her creativity and generosity of time this summer!



[Read More >>](#)

The American Association of Physicists in Medicine sponsored a 10-week summer Diversity Recruitment through Education and Mentoring "DREAM" Program nationally for 7 fellows and Yale was proud to host 3 of the 7 fellows this summer!


Yale study found that in lung cancer patients with oligometastases, a combination of local treatments, in addition to systemic therapy, showed survival benefits



As many as 55% of patients with non-small cell lung cancer (NSCLC) present with stage IV disease at diagnosis. Systemic therapy is the cornerstone for treatment for the patients with stage IV disease.

A Yale Cancer Center study led by Kevin Kim, MD, Professor of Radiology and Biomedical Imaging and Medicine (Medical Oncology) and Section Chief of Interventional Oncology, published in **JAMA Network Open** found that in patients with oligometastases, a combination of local treatments (surgery, radiation and/or thermal ablation) in addition to systemic therapy, vs. systemic therapy alone, showed survival benefits.

[Learn More >>](#)



[Read More >>](#)


Super special thank you to the Connecticut Sun for their generous donation to Smilow Cancer Hospital during #RockThePink earlier this month!




[Read More >>](#)

Follow Yale Cancer Center on Twitter

Follow us on [twitter](#)

 Dr. Sangini Sheth reviews important information for parents to understand about vaccinating their kids against #HPV.

 New research led by .@Aneeschagpar called "practice



Genome screen uncovers new targets for cancer immunotherapy

Immunotherapy has revolutionized the treatment of cancer in the last decade, yet many tumors do not respond to these new therapies. A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system's ability to attack a variety of tumor types, Yale Cancer Center researchers reported Aug. 22 in the journal *Cell*.

"Immunotherapy is not effective in all patients and 70% to 80% don't respond to treatment," said **Sidi Chen, PhD**, Assistant Professor of Genetics and senior author of the study. "We asked: Why don't we take one gene at a time and see which ones are responsible for tumor growth and might be targets for new therapies?"

[Learn More >>](#)

changing" by @NEJM for significant reduction in re-excision rates in women undergoing partial mastectomies.

🐦 Watch the special reason why one of our #Smilow Cancer Hospital nurses bikes in @CTFRide!

🐦 .@NitaAhujaMD, Chief of Surgery at @YNHH, will join us for a discussion on surgical advances on Yale Cancer Answers today at 7:30pm on @wnpr. Tune in to hear her insights & more on her research on #pancreaticcancer or download the podcast.


🐦 In an interview with .@Healthline, @BrigidKillelea explains why #Breastcancer survivors should consider new US Preventive Services Task force guidelines for #BRCA gene testing.

🐦 New research @CellPressNews led by @sidichen shows new ways to unleash the #immune system to attack different #Cancers.

🐦 Promising new findings for children with a rare #braincancer called #DIPG! Research out today in @NatureComms led by @ranjitbindra could lead to new drug therapies to treat this devastating disease.

🐦 A new study @JAMANetworkOpen led by Dr. Kevin Kim found patients with a specific kind of advanced #lungcancer called #oligometastases saw improved survival when given a combination of local treatments in addition to systemic therapy, vs. systemic therapy alone.

🐦 Do you have a personal or family history of #breastcancer or #ovariancancer? The US Preventive Services Task Force has expanded its guidelines to physicians to recommend more women be genetically tested for #BRCA mutations.



A team of investigators at Yale Cancer Center have found a major chink in the armor of an incurable childhood Brain Cancer called Diffuse Intrinsic Pontine Gliomas (DIPG). In a new study, published online in the journal *Nature Communications*, researchers identified an enzyme responsible for producing NAD, a metabolite that is necessary for nearly all of cell life.

"DIPG is such a devastating disease. Children with this cancer, which affects the brain stem when they are between three and five years old, rarely live beyond a year after diagnosis and we have been so stymied in our progress for new therapies," said **Ranjit S. Bindra, MD, PhD**, co-director of the Brain Tumor Center and Associate Professor of Therapeutic Radiology and senior author of the study. "Many drugs have been tested with no success at all. These findings now offer new hope for children with this truly terrible cancer."

[Learn More >>](#)

Training the next generation of physician-scientists is part of our mission! Led by @DrRoyHerbstYale and Dr. Lieping Chen, our new Advanced Training Program T32 will support our #Hematology and #MedicalOncology fellows during years 3 & 4 for #CancerResearch.

Join us on Saturday for a day of networking and education as we look at Paradigm Shifts in Early Stage #BreastCancer Treatment with our colleagues at @MoffittNews and @Rush

Watch why "Team Be Happy" is biking the distance @CTFride next month for #Smilow Cancer Hospital.

Congratulations to our #StemCellTransplant and @Yale_LabMedicine teams on their @FACTunmc re-accreditation! Our program continues its long history of transplant care to patients in Connecticut, around the country and world.

New findings in #breastcancer research journal led by .@SMougalian and Dr. Bridget Killela finds women receiving neoadjuvant #endocrinotherapy had similar rates of breast conservation surgery compared to neoadjuvant #chemotherapy.

Calendar

Yale Cancer Answers

September 1; 7:30 PM

WNPR

Breast Cancer Care

Danielle Bertoni, MD, MPH

[Learn More >>](#)

Schwartz Center Rounds

September 3; 12:00 PM

55 Park Street, Park Street Auditorium

Words Matter: Building our Culture of Respect and Support



New research led by **Anees Chagpar, MD, MPB, MPH, FACS, FRCS(C)**, Professor of Surgery, has been called "practice changing" by the New England Journal of Medicine for significant reduction in re-excision rates in women undergoing partial mastectomies.

The ground-breaking study, recently published in ***Annals of Surgery***, demonstrated that by resecting slightly more tissue around a cancer (cavity shave margins), it reduced positive margin rates and re-excisions by more than half (60-70%) and is effective regardless of surgeon experience, oncoplastic procedures, and other factors.

[Learn More >>](#)

Employee Profile: David Menard

Marlon Pastor-Staton | Yolanda Sydnor |
Andrea Murrell, RN | Maura Shea, RN |
Katherine Tucker | Ena Williams

[Learn More >>](#)

Smilow Screening & Prevention
Informational Table

September 5; 10:00 AM

100 Leibert Rd, Hartford

CT Transit Hartford Division 2019
Employee Health Fair

[Learn More >>](#)

Pharmacology Seminar Series

September 5; 12:30 PM

Brady Memorial Library, B-131

Cracking the Code of Rare Diseases:
Understanding Mechanisms and
Developing New Therapies

Aris N. Economides, PhD

[Learn More >>](#)

Cancer Genetics and Prevention
Program Seminar

September 5; 2:30 PM

Orchard Medical Center, 107-109

[Learn More >>](#)

Advances in Pain Management

September 5; 6:00 PM

Filomena's, Waterford

Sudhir Kadian, MD and Honghui Feng,
MD

[Learn More >>](#)

Hematology Research Seminar Series

September 6; 11:45 AM

Brady Auditorium

Lessons on Sex, Leukemia, and
Therapy Resistance from an Unusual
Malignancy

Andrew Lane, MD

[Learn More >>](#)

Closer to Free Ride 2019

September 7; All Day

As the lead PET Tech in the Department of Radiology and Biomedical Imaging, David Menard has both a managerial and hands-on role. He oversees the day to day tasks of his team, and works in conjunction with the Yale Diagnostic Radiology Clinical Trials team to provide imaging to patients according to various protocols. Previously a computer technician, David came to Yale twelve years ago and enjoys the marriage of technology and patient care his current role provides.



Patients are typically ordered a PET scan for diagnostic, staging, or follow-up purposes. David facilitates communication across multiple modalities to ensure every patient receives high quality care. "Our goal is to provide patients with the newest options available, and to make sure everything about their particular treatment plan is verified before they arrive," said David. "We want to do everything within our power to make this experience as easy and as safe as possible for them."

David was instrumental in performing imaging and collecting data for the National Oncologic PET Registry (NOPR), which was a key factor in the Centers for Medicare and Medicaid Services (CMS) expanding coverage for PET imaging for many cancer types. He was also a crucial part of the reason that Yale was the first in the nation to perform trial imaging for prostate cancer.

Michele K. Pepe, CNMT BS, Senior Manager, Nuclear Medicine & PET CT, Patient Experience, Department

Yale Bowl

[Learn More >>](#)

Yale Cancer Answers

September 8; 7:30 PM

WNPR

Head and Neck Cancer Treatment

Aarti Bhatia, MD, MPH

[Learn More >>](#)

Radiobiology and Radiotherapy
Research Program

September 9; 11:00 AM

Sterling Hall of Medicine, SHMI-304

Outlook for the 2019-2020 R&R Program

Joseph N. Contessa, MD, PhD and
Megan C. King, PhD

[Learn More >>](#)

Yale Cancer Center Grand Rounds

September 10; 12:00 PM

55 Park Street, Park Street Auditorium

Ten Years of HPV Vaccine Impact
Monitoring: lessons Learned and Future
Directions and Exploiting Unexpected
NAD Metabolic Vulnerabilities in
PPM1D-mutant Gliomas

Linda Niccolai, PhD and Ranjit Bindra,
MD, PhD

[Learn More >>](#)

Free Prostate Cancer Screening - PSA
Blood Tests

September 10; 5:00 PM

Greenwich Hospital

[Learn More >>](#)

Cancer Biology Meeting

September 11; 4:00 PM

Brady Memorial Library, B-137

[Learn More >>](#)

Pathology Grand Rounds

September 12; 12:30 PM

Fitkin Memorial Pavilion Auditorium,
LMP 1094

of Radiology and Biomedical Imaging, commented, "Not only has David developed strong relationships with the clinical trial staff resulting in successful data collection for all clinical trials requiring PET imaging, but he also excels in patient and family satisfaction. He goes above and beyond and is a role model for our service."

Recent Publications

Can I Keep My Nipple? Factors Influencing the Surgical Decision between Skin-Sparing and Nipple-Sparing Mastectomy.

Wang M, Huang J, Chagpar AB.

Am Surg. 2019 Jul 1;85(7):768-771.

[Read More >>](#)

Exposure to Polybrominated Diphenyl Ethers and a Polybrominated Biphenyl and Risk of Thyroid Cancer in Women: Single and Multi-Pollutant Approaches.

Deziel NC, Alfonso-Garrido J, Warren JL, Huang H, Sjodin A, Zhang Y.

Cancer Epidemiol Biomarkers Prev. 2019 Aug 6.

[Read More >>](#)

Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer.

Colavito SA, Platt JT, Held MA, Liu Z, Sokup R, Stern DF.

Oncotarget. 2019 Aug 6;10(47):4822-4839.

[Read More >>](#)

PRPF4 is a novel therapeutic target for the treatment of breast cancer by influencing growth, migration, invasion, and apoptosis of breast cancer cells via p38 MAPK signaling pathway.

Park S, Han SH, Kim HG, Jeong J, Choi M, Kim HY, Kim MG, Park JK, Han JE, Cho GJ, Kim MO, Ryoo ZY, Choi SK.

Mol Cell Probes. 2019 Aug 22:101440.

[Read More >>](#)

Minimum Data Elements for Radiation Oncology: An ASTRO.

Harnessing Neuronal Trafficking for Therapeutics in Neurodegeneration

Subhojit Roy, MD, PhD

[Learn More >>](#)

Cancer Genetics and Prevention Program Seminar

September 12; 2:30 PM

Orchard Medical Center, 107-109

[Learn More >>](#)

Free Prostate Cancer Screening - PSA Blood Tests

September 12; 5:00 PM

Greenwich Hospital

[Learn More >>](#)

Smilow Cancer Hospital, Yale Cancer Center and AIM at Melanoma Host

September 12; 5:00 PM

55 Park Street, Park Street Auditorium

Melanoma Symposium

Jonathan Leventhal, MD | Sarah Weiss, MD | James Clune, MD | Kelly Olino, MD, FACS | Harriet Kluger, MD | Laura Donnelly, LCSW | Dwain Fehon, PsyD | Mario Sznol, MD

[Learn More >>](#)

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications

Hayman JA, Dekker A, Feng M, Keole SR, McNutt TR, Machtay M, Martin NE, Mayo CS, Pawlicki T, Smith BD, Kudner R, Dawes S, Yu JB.

Pract Radiat Oncol. 2019 Aug 21.

[Read More >>](#)

Epidemiological analysis of croup in the emergency department using two national datasets.

Hanna J, Brauer PR, Morse E, Berson E, Mehra S.

Int J Pediatr Otorhinolaryngol. 2019 Aug 13;126:109641.

[Read More >>](#)

Effector TH17 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response against Bacterial Infection.

Amezcuca Vesely MC, Pallis P, Bielecki P, Low JS, Zhao J, Harman CCD, Kroehling L, Jackson R, Bailis W, Licona-Limón P, Xu H, Iijima N, Pillai PS, Kaplan DH, Weaver CT, Kluger Y, Kowalczyk MS, Iwasaki A, Pereira JP, Esplugues E, Gagliani N, Flavell RA.

Cell. 2019 Aug 22;178(5):1176-1188.e15.

[Read More >>](#)

PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.

Fons NR, Sundaram RK, Breuer GA, Peng S, McLean RL, Kalathil AN, Schmidt MS, Carvalho DM, Mackay A, Jones C, Carcaboso ÁM, Nazarian J, Berens ME, Brenner C, Bindra RS.

Nat Commun. 2019 Aug 22;10(1):3790.

[Read More >>](#)

Immune cell infiltrate-associated dysregulation of DNA repair machinery may predispose to papillary thyroid carcinogenesis.

Nicolson NG, Brown TC, Korah R, Carling T.

Surgery. 2019 Aug 19.

[Read More >>](#)

The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance.

Sellers CM, Uhlig J, Ludwig JM, Taddei T, Stein SM, Lim JK, Kim HS.

Cancer Med. 2019 Aug 22.

[Read More >>](#)

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Aug 18.

[Read More >>](#)

Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.

Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS.

JAMA Netw Open. 2019 Aug 2;2(8):e199702.

[Read More >>](#)

Insights into novel emerging epigenetic drugs in myeloid malignancies.

Chandhok NS, Prebet T.

Ther Adv Hematol. 2019 Aug 6;10:2040620719866081.

[Read More >>](#)

Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease.

Sellers CM, Uhlig J, Ludwig JM, Stein SM, Kim HS.

Cancer Med. 2019 Aug 20.

[Read More >>](#)

Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer.

Jayakumar A, Bothwell ALM.

J Immunol. 2019 Sep 1;203(5):1095-1103.

[Read More >>](#)

SBRT for Early Stage Laryngeal Cancer: Progress, But Not Quite Ready for Prime Time.

Young MR, Decker RH.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):121-123.

[Read More >>](#)

Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.

Shallis RM, Bewersdorf JP, Boddu PC, Zeidan AM.
Expert Rev Anticancer Ther. 2019 Aug;19(8):717-729.

[Read More >>](#)

Outcomes for urologic oncology procedures: are there differences between academic and community hospitals?

Syed JS, Abello A, Nguyen J, Lee AJH, Desloges JJ, Leapman MS, Kenney PA.

World J Urol. 2019 Aug 16.

[Read More >>](#)

Association between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4.

Ghabili K, Swallow M, Sherrer RL, Syed JS, Khajir G, Gordetsky JB, Leapman MS, Rais-Bahrami S, Sprengle PC.

Urology. 2019 Aug 13.

[Read More >>](#)

Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.

Haines K, Huang GS.

Cancer Res. 2019 Aug 15;79(16):4009-4010.

[Read More >>](#)

Funding Opportunities

The Vera and Joseph Dresner Foundation MDS Research Fund

The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal

hematopoiesis of indeterminate potential (CHIP).

The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:

- Early Career Awards
- Established Investigator Awards

Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.

[Learn More >>](#)

AACR-Bayer Clinical Oncology Research (CORE) Training Fellowships Grant

This grant is designed to encourage exceptional clinical research by bridging close collaboration between academia and industry.

Application Deadline: September 5, 2019

[Learn More >>](#)

Gilead Sciences Research Scholars Program in Hematology/Oncology

This program supports innovative scientific research that will advance knowledge in the field of Hematology/Oncology and provide support for research career development. The awards provide financial support to 3 junior faculty researchers in Canada or the United States for a 2- year period.

Application Deadline: September 6, 2019

[Learn More >>](#)

The Concern Foundation Conquer Cancer Now Award

This Award seeks to fund research in the areas of cancer genetics, cancer cell biology, and cancer immunology.

LOI Due: September 12, 2019

[Learn More >>](#)

The Eppley Foundation for Research

The Eppley Foundation for Research was incorporated in 1947 for the purpose of "increasing knowledge in pure or applied science... in chemistry, physics, and biology through study, research, and publication." The Eppley Foundation supports advanced, novel, scientific research by PhDs or MDs with an established record of publication in their specialties. Candidates with newly awarded doctorates occasionally, but rarely, meet the Foundation's requirements for advanced research.

Letter of Intent Deadline: September 15, 2019

[Learn More >>](#)

NCI Research Specialist Award (R50)

The NCI R50 Award encourages the development of stable research career opportunities for exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators.

LOI Due: September 18, 2019

[Learn More >>](#)

Susan G. Komen Career Catalyst Research Grant

The over-arching goal of this NCI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.

Application Deadline: September 25, 2019

[Learn More >>](#)

Susan G. Komen Career Catalyst Research Grant

The topic area for the FY20 Career Catalyst Research Award is Redefining Metastatic Breast Cancer through Liquid Biopsy. The goal of this focus area is to support outstanding research seeking to use liquid biopsy techniques to improve treatment, detection, and understanding of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026. Komen requests Letters of Intent for research

projects that address one of the following focus areas:

- Refining treatment of metastatic breast cancer
- Early detection of metastatic breast cancer

Applications that fit the focus areas as detailed in the LOI Announcement and include studies that address metastatic breast cancer disparities, or leverage data science to better understand and treat metastatic breast cancer are highly encouraged. The award provides funding up to \$450,000 (direct and indirect costs combined) over 3 years.

Application Deadline: September 25, 2019

[Learn More >>](#)

AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowships Grant

This grant is designed to encourage exceptional clinical research by bridging close collaboration between academia and industry.

September 27, 2019

[Learn More >>](#)

Alex's Lemonade Stand (ALSF) Single-Cell Pediatric Cancer Atlas

Alex's Lemonade Stand Foundation (ALSF) is now accepting applications for the ALSF Single-cell Pediatric Cancer Atlas. ALSF seeks to build a Pediatric Cancer Atlas as an open resource for discovery with an initial goal of producing data that can be harmonized. ALSF seeks researchers to create datasets that profile pediatric cancers at a single-cell resolution level. Single-cell profiling can provide insights into the heterogeneity of cells in a tumor and the surrounding tumor microenvironment, as well as variability in the states of cancer cells, all of which can influence the cancer's response to treatments.

[Learn More >>](#)

Alex's Lemonade Stand Foundation (ALSF) 2020 Crazy 8 Initiative Award

The Crazy 8 Initiative Award will fund research into innovative and rigorous approaches that directly

address the most intractable issues in pediatric cancer research today.

Application Deadline: October 1, 2019

[Learn More >>](#)

Burroughs Wellcome Fund - Career Awards for Medical Scientists

The Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides \$700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Proposals must be in the area of basic biomedical, disease-oriented, or translational research. Proposals in health services research or involving large-scale clinical trials are not eligible.

Application Deadline: October 1, 2019

[Learn More >>](#)

Life Sciences Research Foundation - Postdoctoral Research Fellowship

Since 1983, the Life Sciences Research Foundation (LSRF) has funded nearly 550 outstanding postdoctoral fellows in all areas of the life sciences, and raised more than \$50 million from generous industries, foundations, and individuals to support this effort.

[Learn More >>](#)

Cancer Research Institute - CRI Irvington Postdoctoral Fellowship Program Applications

The Cancer Research Institute is currently accepting applications for its CRI Irvington Postdoctoral Fellowship Program. The CRI Irvington Fellowship furthers career development and supports laboratory research for promising young scientists working under the mentorship of leading immunologists.

Program Note: In recent years, significant advances in immunotherapy have yielded major breakthroughs in cancer treatment. CRI recognizes, however, that getting to the next great breakthrough will require continued investment in fundamental research and training. With this in mind, CRI accepts applications from qualified young scientists at leading universities

and research centers around the world who wish to receive training in fundamental immunology or tumor immunology.

CRI is seeking hypothesis-driven, mechanistic studies in both immunology and tumor immunology that aim to directly impact our understanding of the immune system's role in cancer.

Application Deadline: October 1, 2019

[Learn More >>](#)

Lion Heart Fund for Cancer Research

The Lion Hearts are committed to finding a cure for cancer, and breast cancer in particular. In keeping with this mission, they understand the value of funding bright young minds - providing them with pilot funding to kick-start high potential research projects, and/or supporting innovative work requiring bridge funding.

Deadline for Proposals: November 4, 2019

[Learn More >>](#)